Presenting Companies
Actithera is discovering and developing novel Radiotherapeutics for the treatment of cancer. Actithera’s technology is based on unique medicinal chemistry approaches promising to deliver Radiotherapeutics with with significant differentiation and larger therapeutic windows. Current pipeline includes differentiated best- and first-in-class small molecule and peptide based programs targeting various solid tumors.
Aegle Therapeutics is a clinical-stage biopharmaceutical company developing novel extracellular vesicle (EV) therapies, derived from mesenchymal stem cells, for the treatment of severe and rare inflammatory and immuno-dermatological diseases. Aegle is currently conducting a phase 1/2a studies for the treatment of Dystrophic Epidermolysis Bullosa, a rare pediatric disease characterized by intense skin blistering and chronic inflammation. Aegle’s product pipeline includes other subtypes of EB, graft vs. host disease and burns and has significant potential in multiple immuno-dermatologic indications.
Alphyn is developing breakthrough therapies for the most challenging, severe, and common skin diseases using its proprietary Zabalafin (AB-101) Technology Platform. The Company’s lead product candidate, Zabalafin Hydrogel, is being developed as the first therapeutic for atopic dermatitis or AD, also known as eczema, to directly treat AD’s itch, directly treat the bacteria component of the disease that is increasingly thought to be the cause of AD, and directly treat the inflammation component of AD. Zabalafin Hydrogel successfully completed two Phase 2a clinical trials in AD, which is reported to be the largest dermatology problem worldwide with a projected $41 Billion global market and potential 88 million sufferers. Zabalafin Hydrogel’s Phase 2a clinical trial results were better than competitive drugs, pointing to it becoming the “drug of choice” to treat AD, significantly de-risking the Company.
Amorphical Ltd., an Israeli biotechnology company, is pioneering innovative therapies for metabolic, bone, and inflammatory diseases, utilizing a proprietary nano-amorphous minerals technology with impressive preclinical and clinical results across various diseases, bolstering confidence in its novel therapeutic approaches. The company’s bioactive substances enable efficient delivery by targeting damaged tissues, utilizing their nanometric structure and amorphous molecular arrangement. Hence, Amorphical presents game-changing solutions for two critical biomedical challenges: (a) inefficient mineral absorption and (b) local acidity (acidosis) associated with severe inflammatory conditions of life-threatening diseases. Strategically, Amorphical initiated its clinical trial pursuit with an orphan disease (hypoparathyroidism) to expedite FDA approval at the fastest regulatory track, and is simultaneously conducting additional clinical trials for treating osteoporotic fractures, pancreatic cancer, and Crohn's disease to validate its mineral-based therapeutics. Amorphical is upgrading its manufacturing facilities to meet pharmaceutical GMP standards, actively pursuing strategic partnerships, and investing in its clinical programs, with the goal of a Nasdaq IPO planned for 2026.
Angiex develops TM4SF1-directed antibody-drug conjugate therapies for solid cancers. Angiex drugs have three novel and differentiated mechanisms of action with potential to benefit all solid cancer patients, and exceptional safety. Angiex’s lead drug, AGX101, is currently performing well in Phase 1. The company is seeking to raise ~$5 million to bridge to patient responses, after which a Series A round will be raised from institutional therapeutics investors.
Apricity Health is a developer of a monitoring and care management platform designed for cancer treatment. The company's platform incorporates real-time patient data to deliver actionable insights to clinicians at points of care, enabling clients to access the latest information about cancer treatments.
Avirmax, Inc. based in San Francisco Bay Area, is dedicated to innovate, develop and manufacture adeno-associated virus (AAV) vector mediated biotherapeutics using its proprietary protein therapeutics and BAC-to-AAV technologies. Avirmax Adeno-associated Vector Innovation Platform (AAVIP), enables us to become a “powerhouse” of rAAV therapeutics for its very infectious AAV vectors with high titers at production and enhanced expression of gene of interest (GOI) in target cells. Our ultimate goal is to deliver patients with the effective, safe, long-acting AAV-mediated biotherapeutics at the most affordable and accessible manner. Avirmax, Inc is dedicated to innovate and develop novel technologies to address current challenges in viral vector production based on its state of the art AAV bioprocess technologies in combination with Virovek’s BAC-to-AAV insect system. Avirmax has established robust rAAV vector production technologies for small and large-scale applications using Sf9-Baculovirus system.
Bexion Pharmaceuticals, a clinical-stage biopharmaceutical company, is advancing a new class of biologic therapy aimed at treating solid tumors and chemotherapy-induced peripheral neuropathy (CIPN), with the potential to expand its portfolio into additional cancer types and broader neuropathic pain treatments. Bexion has generated promising clinical data across various solid tumor types, including its lead indication, colorectal cancer, where the company has completed enrollment in the 30-subject expansion cohort of a Phase 1b/2 study. Additionally, Bexion has completed a blinded, placebo controlled, proof-of-concept study for treating CIPN.
BioAegis Therapeutics is a private, clinical stage company pioneering a novel approach to conquering diseases driven by excess inflammation and without suppressing immune function. It’s portfolio of products is built around restoring plasma gelsolin (pGSN), a key immune system protein and master regulator of inflammation. The protein’s pleiotropic mechanism is associated with NLRP3 inflammasome activation, quorum sensing and other mechanisms, and ideal for addressing many complex inflammatory diseases. The Company holds exclusive worldwide rights to technology through Harvard’s-Brigham and Women’s Hospital, with over 40 issued patents for inflammatory disease, infection, renal disease and neurologic disease. It’s lead product is currently in a 600-patient global Phase 2 trial for patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS), and is in part supported by a $20M contract with BARDA’s Division of Research, Innovation, and Ventures (DRIVe).
Blue Earth Therapeutics is a clinical stage company dedicated to advancing next generation targeted radiotherapeutics to treat patients who have cancer and has been incubated within the Bracco family of companies. With proven management expertise across the spectrum of radiopharmaceutical and oncology drug development, as well as biotechnology start‐up experience, the Company aims to innovate and improve upon current technologies and rapidly advance new targeted therapies for serious diseases. Blue Earth Therapeutics has an emerging pipeline initially focused on prostate cancer. For more information, please visit: https://www.blueearththerapeutics.com.
CARTx Therapeutics is a pre-IND biotech company pioneering affordable and accessible off-the-shelf CAR-T therapies. Using patented CRISPR/AAV technology, CARTx edits healthy donor γδT-cells to knock out unwanted genes and site-specifically insert CARs. This versatile platform enables treatment of a wide range of hematological and solid tumors, as well as certain autoimmune diseases, simply by switching the CAR. Manufacturing of our off-the-shelf therapies is highly scalable, enabling a 90% lower manufacturing cost and faster availability to patients than present autologous CAR T-cell therapies. Having obtained positive in vivo data, CARTx now plans to initiate Phase 1 clinical trials in Q1-2026.
Cell BioEngines, Inc is a clinical-stage biotech company based in New York, focused on developing allogeneic ‘off-the-shelf’ stem cells and their derived therapies as ‘drugs’ for human disease treatment. The company has a ‘plug-and-play’ universal blood stem cell platform to address donor source availability, cellular potency, and scaling complexities in producing multiple clinical-grade cell products. Its leading clinical product, SAVI-CORD, is an expanded, readily available, off-the-shelf blood stem cell therapy for transplantation in blood cancer patients, designed to enhance the graft-versus-tumor effect without genetic modification.
Chariot Biosciences is a synthetic biology company pioneering Simmbions™, a proprietary platform of engineered symbiotic microbes for sustained drug delivery. Designed to address the challenges of chronic biologic therapies, Simmbions™ enable continuous therapeutic release from a single subcutaneous injection, reducing treatment burden and improving patient outcomes. This innovative approach has the potential to overcome key barriers to adherence, including frequent dosing and logistical complications. By harnessing the power of synthetic biology, Chariot Biosciences is redefining drug delivery to improve efficacy and accessibility across multiple chronic diseases.
Innovative medical device company and manufacturers of the COMBAT BRS (Bladder) and COMBAT PRS (Peritoneal) systems. The BRS delivers HIVEC- Hyperthermic Intra-Vesical Chemotherapy treatment through a closed self regulating recirculation system to significantly increase the effectiveness of Mitomycin C (MMC) in Non Muscle Invasive Bladder Cancer (NMIBC). The PRS delivers HIPEC+ Agitation - Hyperthermic Intraperitoneal Chemotherapy plus agitation to optimise the HIPEC delivery while treating cancers within the peritoneal cavity including ovarian, colo -rectal, pancreatic and gastric.
Converge Consulting is a management consulting firm exclusively serving the life sciences industry. We focus on helping clients achieve important business objectives by bridging the gap between sound strategy and reliable execution. Clients benefit from the experience and capabilities of our practitioners, direct interaction with our senior team, our commitment to delivering superior service and exceeding our clients` expectations.
Dioseve is a pioneering biotechnology startup, dedicated to advancing fertility treatments through innovative regenerative medicine. Our flagship technology, DIOS-101, utilizes ovarian cells derived from induced pluripotent stem (iPS) cells to mature immature oocytes in vitro, significantly improving fertility outcomes.
Drusolv Therapeutics is developing a patent-protected, clinically distinct formulation of oral atorvastatin for early intervention in a blinding eye disease called age-related macular degeneration (AMD). This is a $13B per year, completely unmet need. The objective is to exit via acquisition in three years after a pending, IND-approved Phase 2 trial, and recent ophthalmic drug M&A transactions after Phase 2 support an exit valuation of $1B. We are currently syndicating a $20M Series A round that will carry us through acquisition.
Duo Oncology, founded by oncologists, is developing tumor-penetrating nanomedicines to upgraded the foundations of cancer medicine. Duo’s patented platform prodrug chemistry releases creates nanomedicines that penetrate established tumors to reduce toxicity and improve patient outcomes.
Eurofins CDMO Alphora Inc. is a Canadian contract development and manufacturing organization (CDMO) providing integrated solutions for pre-clinical and clinical services in Drug Substance (Active Pharmaceutical Ingredient), Drug Product, Solid State Research & Development and Biologics. We specialize in a full suite of drug development services and manufacturing capabilities at our FDA and Health Canada-approved facilities, delivering sustainable and flexible solutions that support biopharmaceutical companies from pre-clinical phases to commercialization.
Frantz Viral Therapeutics (FVT) is advancing the landscape of care for human papillomavirus (HPV)-induced pre-cancers (intraepithelial neoplasia). There are no approved non-surgical therapies to treat these indications, which affect nearly 1 million people in the US each year alone. FVT is well positioned to be the first to market in this space with a self-administered topical formulation of artesunate. Phase 1/2A studies were completed with excellent safety data and promising efficacy results. Three randomized Phase 2B studies at major US medical research institutions are currently enrolling in cervical, vulvar, and anal indications, with interim analyses planned for cervical and anal indications in April.
HBC Immunology’s (HBCI) mission is reversing drug resistance using gene expression-targeting peptides. Drug resistance emerges through adaptive changes in gene expression patterns. Our innovative approach targets and reverses these treatment-induced transcriptional changes, restoring therapeutic sensitivity and extending the duration of clinical benefit. Our lead program targets a critical unmet need in metastatic castration-resistant prostate cancer (mCRPC): acquired resistance to androgen receptor (AR) inhibition. In xenograft studies, FT-002a-O, our first-in-class orally bioavailable peptide therapeutic, has demonstrated robust re-sensitization to the leading AR-treatment, enzalutamide, with an IND submission on-tract in Q4/2025.
HERVolution Therapeutics is engineering novel immunotherapies that empower the immune system to target HERVs, a class of dark genome antigens impacting cancer as well as metabolic and aging-related diseases.
Imagion’s MagSense® imaging technology improves cancer detection compared to conventional imaging technologies by adding molecular specificity without using radioactivity. MagSense® agents are a new class of MRI imaging agents that can transform how MRI is used to detect cancer. Agents for HER2 Breast cancer, Prostate cancer, and Ovarian cancer are in the pipeline.
Immunophotonics, Inc. is a private biotechnology company that focuses on the development of a new treatment for patients with solid cancers. Our pioneering efforts aim to prevent tumors from coming back, and to allow cancer patients to lead healthy lives without the need for further therapies. Pre-clinical and clinical data indicate that our lead asset, IP-001, can transform local tumor destruction treatment into a systemic immune therapy. The addition of IP-001 to standard-of-care tumor ablation treatments is simple and has the potential to make every one of these destruction methods more effective. The company is preparing for a phase 2/3 clinical trial in collaboration with a large medical society and key opinion leaders in the tumor destruction field.
Kopra Bio makes genetically engineered viruses that teach your immune system to kill cancer using technology we developed at UCSF. In the most challenging brain cancer model, we improve survival from 0% with the current FDA approved treatment to 90% with our treatment. Our virus infects cancer cells, spreads throughout tumors, and hijacks them to produce immunostimulatory cytokines. The cytokine signals recruit the immune system which then kills the tumor. Kopra Bio was founded by world leading experts in oncolytic viruses targeting the tumor microenvironment and is backed by leading investors like Metaplanet and Y Combinator.
Lemonex is a biotech company developing safe and thermostable mRNA vaccines and gene therapeutics using its proprietary DegradaBALL™ drug delivery platform. DegradaBALL™ enhances targeted drug delivery, reducing systemic side effects, making it ideal for anti-cancer mRNA vaccines, gene therapies, and immuno-oncology applications. It also enables effective extra-hepatic siRNA delivery through multiple administration routes (SC, IM, IT, IV) and offers thermostability, minimizing cold-chain challenges and drug wastage. Phase 1 clinical trials of LEM-mR203 showed a one-third reduction in adverse events compared to Moderna’s data (NEJM) while enhancing cellular immunogenicity. Lemonex is advancing LEM-mR203 through a strategic partnership with CEPI to drive innovation in pandemic preparedness and mRNA vaccine development.
Modra (Modulated Oral Drug Absorption) Pharmaceuticals B.V. is a spin-out from two internationally acclaimed centers of excellence in oncology, the ‘Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)’ and the MC Slotervaart (Slotervaart) in Amsterdam. Modra Pharmaceuticals is a clinical stage company that develops new treatment paradigms by enabling oral bioavailability of existing anticancer drugs, “the iv to oral switch”, to improve cancer therapy and supportive care. Modra Pharmaceuticals has several products in preclinical and clinical development including oral formulations of docetaxel and paclitaxel.
Nanocan Therapeutics Corporation is a Princeton, New Jersey based early stage biotechnology company developing cutting-edge, nanotechnology based innovations for therapeutic medicines to treat certain cancers where current interventions are insufficient. The Company’s inventions deploy smart radiotherapy biomaterials (nanoparticle drones), as a drug-delivery platform. Nanocan’s nanoparticle drones can be employed to sustainably deliver different drug payloads – including immunotherapy drugs, chemotherapy drugs, and phytomedicines – precisely to disease sites or targets, with greater therapeutic efficacy. Through its partnerships with leading academic research institutions, Nanocan is rapidly developing therapies that may ultimately result in new standards of care to help improve the lives of cancer patients. Nanocan is committed to making its disruptive innovations available to cancer patients in the U.S. and globally, including Low and Middle-Income Countries (“LMICs”), starting with countries in Africa.
Our mission is to equip life science entities with tailored funding solutions that drive excellence and innovation. By bridging financial gaps and unlocking key resources, we empower organizations to unlock their scientific funding potential and deliver impactful innovations that redefine the future of human health on a global scale.
Ordaōs is a human-enabled, machine-driven drug design company. Our miniPRO™ proteins help drug hunters deliver treatments that are safer and more effective than traditional discovery methods.
Pilatus Biosciences pioneers metabolic immunotherapy, tackling hard-to-treat cancers by reprogramming the immune system. Our lead candidate, PLT012, blocks CD36 to enhance immune responses and overcome resistance in liver and metastatic cancers. With strong preclinical efficacy, a favorable safety profile, and applications beyond oncology, Pilatus is advancing next-generation therapies to address critical unmet medical needs.
PredxBio is a TechBio company, headquartered in Pittsburgh, harnessing the power of spatial biology to unravel the hidden circuitries of the tumor microenvironment and getting to the “Why?” of cancer. Demonstrating a clear impact today, we have established an impressive accuracy in predicting patient responses to immunotherapy across the most critical cancers. Our ground-breaking platform aims to transform cancer care with next generation spatial analytics and explainable AI, thereby accelerating advancements in drug development and clinical trials. PredxBio opens a new era with far-reaching implications for biomarker discovery and clinical research with promising results in understanding disease progression and response to therapy. For more information, go to info@predxbio.com.
Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer Therapy (NGC) drugs with improved safety and efficacy. Our NGC drugs are modifications of existing FDA-approved oncology therapies including capecitabine, gemcitabine and irinotecan, resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining our novel oncology pipeline with proven cancer-killing active molecules and our Regulatory Science Approach, we believe we can develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.
PureIMS is a clinical stage pharmaceutical company focused on developing and commercializing innovative inhaled therapies, based on its proprietary dry powder inhaler Cyclops®. The focus is on the treatment of systemic and respiratory diseases with significant unmet medical need. PureIMS has an in-house pipeline of products available for out-licensing. In addition to that the company partners with pharmaceutical, diagnostics and vaccine companies in search for a prefilled easy-to-use dry-powder inhalation device for their products, NCE’s and NBE’s in a wide range of indications, including diagnostics.
Quiver Bioscience has built a first-of-its-kind platform that measures neuronal activity at a scale and depth never before possible in neuroscience. We are using this platform to build the world's most information-rich neuronal insight map via our "Genomic Positioning System", enabling: Translational Models: Our patient-derived stem-cell models enhance translatability through proprietary stem cell differentiation protocols that capture disease phenotypes. Transformative Tools: Our high-throughput optogenetic screening instruments record electrophysiological behavior across hundreds of cells in parallel, collecting high dimensional data from each cell measured. AI-Driven Insights: Advanced analytics mine our high-dimensional data to reveal key disease phenotypes and therapeutic candidates with higher in vivo potential. Our tools and advanced AI models are supercharging our therapeutics portfolio with better efficacy, lower toxicity, and improved in vivo translatability driven by our expanding neurobiological understanding. Our lead therapeutic programs include first-in-class/best-in-class compounds for the treatment of neuropathic pain and genetically-defined neurodevelopmental disorders.
Rakuten Medical is a clinical and commercial-stage biotech company advancing its investigational Alluminox™ platform, which is based on photoimmunotherapy. The company is developing the platform consisting of drug and device to treat cancers. Its lead asset, ASP-1929, an antibody-dye conjugate targeting EGFR, is currently in a global Phase 3 trial in combination with anti-PD-1 therapy. ASP-1929 has already received marketing approval in Japan since 2021 for unresectable, locally advanced, or recurrent head and neck cancer. As of today, the company has completed over 800 commercial treatments in Japan.
RNA Nanobiotics was established to advance the RNA nanoparticle technology developed by Dr. Peixuan Guo at Ohio State University into an innovative targeted delivery system able to improve the therapeutic outcome of patients with cancer. Our proprietary RNA Nanotechnology Platform allows for Targeted Delivery of RNAi, Radioisotopes and Chemotherapeutics for safe and effective cancer treatments. The nanoparticles are made of synthetic RNA and are engineered to contain aptamer targeting sequences, modified nucleoside drugs and microRNA and RNAi drugs into the nano particles which morph into the drugs when they reach and are incorporated into the target cells.
SciTech is a clinical stage, biopharmaceutical company that has developed a proprietary nano-delivery system (SciTech Drug Delivery Platform - SDP) to enable intravenous (IV) delivery of water-insoluble drugs. One such challenged drug or active pharmaceutical ingredient (API) is fenretinide, the API in SciTech's lead drug candidate, has been shown in numerous clinical trials to be a relatively safe and effective anticancer therapy with targeted cancer destroying activity. The patented combination of the new SDP and fenretinide has led to SciTech’s first drug candidate, ST-001 nanoFenretinide, that holds the promise of improving and saving many lives.
Teclison is a clinical stage oncology company advancing an immunotherapy treatment for solid tumors utilizing a three-pronged approach that: (1) induces tumor necrosis; (2) expands anti-tumor T cells to synergize with immune checkpoint inhibitors; and (3) facilitates the direct and cost-effective expansion of anti-tumor immunity from PBMCs. Our lead asset, TEC-001, is initially targeting advanced liver and colorectal cancer, with additional cancer indications in the pipeline. Teclison’s innovative platform has shown broad reach across solid tumor types in early clinical trials, providing Teclison access to numerous multi-billion dollar markets.
Ternalys' synthetic, biologically recognized SAGUARO platform (US patent issued 2024) utilizes the clustering properties of microRNAs and non-coding RNAs (aptamers etc.) to simultaneously and homogeneously deliver multiple miRNAs and non-coding RNAs directly to tumor cells. By reversing the increase/decrease in expression that occurs as tumors respond to chemotherapy or radiation, the SAGUARO approach solves the limitations of single gene targeted therapies and counters cancer’s epigenetic mechanisms of resistance and survival. This approach paves the way for focused therapeutics to kill the tumors, and represents a new treatment paradigm for intractable cancers. Ternalys’ first target tumor is recurrent glioblastoma, where the ability of the SAGUARO platform to replace or remove miRNA’s has been shown in preclinical models to dramatically increase survival rates. Ternalys is raising a seed round to complete preclinical studies which the company anticipates will lead directly to clinical testing in recurrent glioblastoma.
UB Therapeutics develops innovative cyclic peptides targeting resistance in multiple myeloma, focusing on disrupting ubiquitin chains to induce cancer cell apoptosis. With preclinical results showing significant efficacy, UB Therapeutics is positioned to revolutionize treatment options for resistant patients.
Variational AI has developed the Enki™ foundation model for small molecule drug discovery. Enki rapidly generates potent, selective, and synthesize leads for almost 600 targets across many therapeutic areas and is trusted by both biotechs and pharma for their early-stage discovery programs. Based in Vancouver, Canada, Variational AI is also developing a portfolio of early-stage assets in oncology, IO, I&I, CNS, and other indications. We are post-Seed/pre-Series A with investment from Nimbus Synergies, Merck Global Health Innovation, and Flying Fish Venture Capital.